Atea Pharmaceuticals, Inc. (AVIR) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
AVIR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Atea Pharmaceuticals, Inc. (AVIR) trades at a price-to-earnings ratio of -2.9x, with a stock price of $5.54 and trailing twelve-month earnings per share of $-1.86.
The current P/E is 103% below its 5-year average of 105.0x. Over the past five years, AVIR's P/E has ranged from a low of 6.6x to a high of 441.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, AVIR trades at a 113% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, AVIR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AVIR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AVIR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $693M | 53.9 | - | +82% | |
| $166B | 19.8 | 0.15Best | +1684%Best | |
| $358B | 85.5 | - | -1% | |
| $277B | 15.4Lowest | 0.73 | +8% | |
| $74B | 17.1 | 2.70 | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AVIR Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $5.69 | $0.36 | 15.7x | -85% |
| FY2022 Q2 | $7.10 | $0.12 | 59.2x | -44% | |
| FY2022 Q1 | $7.22 | $0.52 | 13.9x | -87% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $8.94 | $1.36 | 6.6x | -94% |
| FY2021 Q3 | $35.06 | $0.25 | 140.2x | +34% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $21.48 | $0.37 | 58.1x | -45% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $61.75 | $0.14 | 441.1x | +320% |
Average P/E for displayed period: 105.0x
See AVIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVIR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVIR — Frequently Asked Questions
Quick answers to the most common questions about buying AVIR stock.
Is AVIR stock overvalued or undervalued?
AVIR trades at -2.9x P/E, below its 5-year average of 105.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does AVIR's valuation compare to peers?
Atea Pharmaceuticals, Inc. P/E of -2.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is AVIR's PEG ratio?
AVIR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.